Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States

This proclamation designates adjusted import measures for pharmaceuticals and their active ingredients, responding to a Commerce Department section 232 finding that imports of patented pharmaceuticals and APIs threaten national security and economic resilience as of April 2, 2026. It directs the Secretary of Commerce and other federal agencies to implement actions such as negotiating onshoring agreements tied to Most-Favored-Nation pricing and imposing significant tariffs and other trade measures to reduce reliance on foreign production, noting that about 53 percent of patented pharmaceutical products and only 15 percent of patented APIs by volume were produced domestically as of 2025.